Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP | O00591 | 1/20 | 0.44 |
| ▸ | GABRD | O14764 | 1/20 | 0.44 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.44 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.44 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.44 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.44 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.44 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.44 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.44 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.44 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.44 |
| ▸ | GABRE | P78334 | 1/20 | 0.44 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.44 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.44 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.44 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.44 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.41 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8623675 | 0.98 | GABRP (0.43) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL4623168 | 0.88 | FFAR1 (0.46) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL6937078 | 0.84 | FFAR1 (0.55) | PYCR1FFAR1FFAR4KCNH2MMP2 | |
| SCHEMBL1897376 | 0.84 | FFAR1 (0.55) | PYCR1FFAR1FFAR4KCNH2MMP2 | |
| SCHEMBL4621099 | 0.82 | PYCR1 (0.40) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL797749 | 0.82 | FFAR1 (0.40) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL15588318 | 0.80 | FFAR1 (0.42) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL28377872 | 0.80 | KCNH2 (0.56) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL4385059 | 0.78 | APP (0.45) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL6045084 | 0.78 | GABRP (0.44) | GABRPGABRDGABRA1GABRB1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8067605-B2 | Process for production of piperidine derivatives | ALBANY MOLECULAR RESEARCH, INC. (US) | 2011-11-29 | — | — | US | disclosed |
| US-8067604-B2 | Process for production of carebastine | ALBANY MOLECULAR RESEARCH, INC. (US) | 2011-11-29 | — | — | US | disclosed |
| US-20110071295-A1 | PROCESS FOR PRODUCTION OF PIPERIDINE DERIVATIVES | ALBANY MOLECULAR RESEARCH, INC. (US) | 2011-03-24 | — | — | US | disclosed |
| US-20110065923-A1 | PROCESS FOR PRODUCTION OF CAREBASTINE | ALBANY MOLECULAR RESEARCH, INC. (US) | 2011-03-17 | — | — | US | disclosed |
| EP-0453503-B1 | PHENYL NAPHTHALENES HAVING LIQUID CRYSTALLINE PROPERTIES | SECR DEFENCE BRIT (GB) | 1995-03-22 | — | — | EP | disclosed |
| US-5252253-A | Phenyl naphthalenes having liquid crystalline properties | THE SECRETARY OF STATE FOR DEFENCE IN HER BRITANNIC MAJESTY'S GOVERNMENT OF THE UNITED KINGDOM OF GREAT BRITAIN AND NORTHERN IRELAND (GB) | 1993-10-12 | — | — | US | disclosed |
| EP-0295056-B1 | ANTI-INFLAMMATORY FURANONES | ALLERGAN, INC (US) | 1992-08-05 | — | — | EP | disclosed |
| US-5134128-A | Immunosuppressive and antiproliferative activity for psoriasis and calcium homeostasis | ALLERGAN, INC. (US) | 1992-07-28 | — | — | US | disclosed |
| EP-0453503-A1 | PHENYL NAPHTHALENES HAVING LIQUID CRYSTALLINE PROPERTIES. | SECR DEFENCE BRIT (GB) | 1991-10-30 | — | — | EP | disclosed |
| WO-1990008119-A1 | PHENYL NAPHTHALENES HAVING LIQUID CRYSTALLINE PROPERTIES | THE SECRETARY OF STATE FOR DEFENCE IN HER BRITANNIC MAJESTY'S GOVERNMENT OF THE UNITED KINGDOM OF GREAT BRITAIN AND NORTHERN IRELAND (GB) | 1990-07-26 | — | — | WO | disclosed |
| EP-0295056-A1 | Anti-inflammatory furanones | ALLERGAN, INC (US) | 1988-12-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110071295-A1 | PROCESS FOR PRODUCTION OF PIPERIDINE DERIVATIVES | HADHB, CPT1B, PDHB | GABRP 10/4885GABRD 67/4885GABRA1 158/4885 |
| US-20110065923-A1 | PROCESS FOR PRODUCTION OF CAREBASTINE | GABRE, GABRB3, GABRB2 | GABRP 8/4885GABRD 24/4885GABRA1 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.